Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or β-interferon

Journal of Dermatology

Volumn 23, Issue 1, 1996, Pages 6-15

  Nakayama, Juichiro ^a   Takeuchi, Minoru ^a   Mayumi, Hisanori ^a   Nagae, Shonosuke ^a   Matsuda, Kazuhisa ^a   Yasui, Hisataka ^a   Takahashi, Shosuke ^a   Hori, Yoshiaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

interferon; carboplatin; HILP; immunological parameters; malignant melanoma

Indexed keywords

BETA INTERFERON; CARBOPLATIN; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 2; MELPHALAN; NIMUSTINE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CASE REPORT; CLINICAL TRIAL; FEMALE; HUMAN; HYPERTHERMIA; INTRAARTERIAL DRUG ADMINISTRATION; LEG PAIN; LIMB PERFUSION; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; SKIN CANCER; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYSTEINYLDOPA; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON-BETA; KILLER CELLS, NATURAL; LEG; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; NAUSEA; REMISSION INDUCTION; SKIN NEOPLASMS; VOMITING;

EID: 0030043919     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chussen F, Kruger I, Groth W, et al: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma, Cancer, 61: 654-659, 1988.
2. Lejeune FJ, Liénard D, Douaihy EI, et al: Results of 206 isolated limb perfusions for malignant melanoma, Eur J Surg Oncol, 15: 510-519, 1989.
3. Skene AI, Bulman AS, Williams TR, et al: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb, Br J Dermatol, 77: 765-767, 1990.
4. Kettelhack C, Kraus T, Hupp T, et al: Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma, Eur J Surg Oncol, 16: 370-375, 1990.
5. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs, World J Surg, 16: 227-233, 1992.
6. Edwards MJ, Boddie AW, Ames FC, Mcbride CM: Isolated limb perfusion for Stage I melanoma of the extremity: A comparison of melphalan and dacarbazine (DTIC), Southern Med J, 82: 985-989, 1989.
7. Coit DG: The role of surgery in cutaneous malignant melanoma, in Nathanson L (ed): Current Research and Clinical Management of Melanoma, Kluwer Academic Publishers, USA, 1993 pp 297-334.
8. Nakayama J, Toyofuku K, Urabe A, et al: A combined therapeutic modality with hyperthermia and locally administered rIFN-β inhibited the growth of B16 melanoma in association with the modulation of cellular infiltrates, J Derm Sci, 6: 240-246, 1993.
9. Nakayama J, Urabe A, Toyofuku K, et al: Suppression of murine melanoma growth with a combination of microwave hyperthermia and local injection of interleukin 2, Br J Dermatol, 130: 717-724, 1994.
10. Nakayama J, Moroi Y, Toshitani A, et al: Responses of B16 melanoma cell lines, F1 and F10, to hyperthermia, lymphokine-activated killer cells and a combination of both in vitro, Br J Dermatol, 126: 131-136, 1992.
11. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression, Cancer, 73: 629-636, 1994.
12. Toyofuku K, Nakayama J, Hori Y: Clinical and immunohistochemical study of a combined therapeutic modality of local microwave hyperthermia and intratumoral IFN-β injections in murine and human melanomas, Jpn J Dermatol, 104: 1729-1736, 1994. (in Japanese)
13. Stehlin JS: Hyperthermic perfusion with chemotherapy for cancer of the extremities, Surg Gynecol Obstet, 129: 305-308, 1969.
14. Stehlin JS Jr, Giovanella BC, Gutierrez AE, et al: Fifteen years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther One, 18: 177-182, 1984.
15. Fukuzawa K, Horikoshi T: Inhibitory effect of human fibroblast interferon (HM IFN-β) on the growth and invasive potential of cultured human melanoma cells in vitro, Br J Dermatol, 126: 324-330, 1992.
16. Sakurai M, Iigo M, Ozaki A, et al: Inhibitory effects of murine recombinant interferon (β) on the pulmonary metastasis of B-16 melanoma, Jpn J Cancer Res (Gann), 77: 774-781, 1986.
17. Sutherland CM, Mather FJ, Kremenz ET: Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion, Surg Gynecol Obstet, 164: 111-118, 1987.
18. Cumberlin R, Moss ED, Lassus M, Friedman M: Isolation perfusion for malignant melanoma of the extremity: A review, J Clin Oncol, 3: 1022-1031, 1985.
19. Liénard D, Ewalenko LD, Delmotte JJ, et al: Highdose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J Clin Oncol, 10: 52-60, 1992.
20. Liénard D, Lejeune F, Ewalenko I: In-transit metastases of malignant melanoma treated by high dose rTFN-α in combination with interferon-γ and melphalan in isolation perfusion, World J Surg, 16: 234-240, 1992.
21. Krementz ET, Muchmore JH, Carter RD, Sutherland CM: Multiple perfusion for melanoma, Melanoma Res, 4: suppl 1, 39-44, 1994.
22. Nakayama J, Takeuchi M, Mayumi H, et al: Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-β for the treatment of malignant melanoma of the leg, J Dermatol (Tokyo), 21: 915-922, 1994.